$LITS

Lite Strategy, Inc.

Lite Strategy is a pharmaceutical company developing voruciclib and zandelisib, drug candidates that it is evaluating for potential nononcologic uses or out-licensing and sale. Voruciclib is an oral CDK9 inhibitor in preclinical development for nononcologic diseases. Zandelisib is an oral, once-daily selective PI3Kδ inhibitor; Lite Strategy is not conducting clinical trials for it and is assessing out-licensing or sale opportunities. The company sold ME-344, a mitochondrial inhibitor, to Aardvark Therapeutics, Inc. in October 2024. Lite Strategy also holds Litecoin tokens as a primary reserve asset. It writes covered call options on some holdings through contracts with GSR Markets Ltd, a strategy intended to generate liquidity and income while retaining exposure to the assets. It is headquartered in San Diego, California.

No enriched coverage for $LITS in the last 7 days.

$22K
—
Flynn James P
0%
See all $LITS insider activity →

Lite Strategy reports Q1 results (NASDAQ:LITS)

Lite Strategy (LITS) reported Q1 results, showing a 52% reduction in cash used for operations and a 24% decrease in G&A expenses year-over-year. The company held $4.3M in cash, $46.2M in digital assets, with total assets of $58.4M and liabilities of $1.7M, according to the press release.

Lite Strategy, Inc. (LITS): Unregistered Sales of Equity Securities

Lite Strategy, Inc. (LITS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously reported, on July 22, 2025, Lite Strategy, Inc. (the “Company”) entered into an Advisory Agreement (the “Advisory Agreement”) with Green Dragon Investments LLC (“Green Dragon”), pursuant to which the Company agreed

LITS sentiment & insider activity

Recent LITS coverage spans earnings, insider activity and corporate actions.

In the last 30 days, LITS insiders filed 1 SEC Form 4 transaction — 1 purchase ($22K) and no sales. The most active reporter was Flynn James P with 1 filing.

What's driving LITS

AlphAI scores every news story that mentions LITS with an AI model for sentiment and relevance, and aggregates insider trades from Lite Strategy, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $LITS

Score
$LITSLowOffering· 517.47K · closed

Lite Strategy, Inc. (LITS): Unregistered Sales of Equity Securities

Lite Strategy, Inc. (LITS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously reported, on July 22, 2025, Lite Strategy, Inc. (the “Company”) entered into an Advisory Agreement (the “Advisory Agreement”) with Green Dragon Investments LLC (“Green Dragon”), pursuant to which the Company agreed

Lite Strategy (LITS): Litecoin Treasury Strategy Enters the Execution Test

Lite Strategy, Inc. (LITS), formerly MEI Pharma, now focuses on Litecoin as a treasury reserve asset. By fiscal 2026, it accumulated 832,716 Litecoin tokens and operates debt-free. The company's strategy includes active treasury management, share repurchases, and investments in the Litecoin ecosystem. Management aims to increase Litecoin backing per share, but investors face volatility and valuation questions due to mark-to-market accounting and regulatory risks.

Lite Strategy, Inc. FY 2026: Net loss $(71.2M), EPS $(2.06) — 10-K Summary

Lite Strategy, Inc. reported a net loss of $71.2M for FY 2026, worsening from a $15.9M loss in FY 2025, with no revenue in either year. The company pivoted to Litecoin (LTC) as its primary reserve strategy, discontinuing oncology programs and focusing on non-oncologic R&D. Management initiated share repurchases and a covered call options program to manage capital and LTC exposure.

$LITSMedBuyback · 4.9M

Lite Strategy, Inc. (LITS): Results of Operations and Financial Condition

Lite Strategy, Inc. (LITS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share Lite Strategy Buys Back Roughly 4.9 Million Shares at an Average Price of $1.11 with No Debt Incurred SAN DIEGO, July 30, 2026 — Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Str

James Flynn Purchases 70,000 Shares of Lite Strategy (NASDAQ:LITS) Stock

Director James Flynn recently acquired 70,000 shares of Lite Strategy (NASDAQ:LITS) for $98,000, significantly increasing his direct ownership. This purchase occurred shortly after the company authorized a $25 million share buyback program, suggesting management views the stock as undervalued. Lite Strategy shares are currently trading around $1.41, with a market capitalization of $51.86 million, and analysts generally rate the stock as a "Sell".

Related tickers